Hengrui Pharma (600276.SH) Stock Community - Hot Topic Discussions - Longbridge

Quote List Quote List

Event Tracking

Dec19

Hengrui Pharmaceutical's Subsidiary Obtains Clinical Trial Approval for Leuprorelin Acetate Microspheres Injection

12:01

Hengrui Medicine Subsidiary Receives Clinical Trial Approval Notice for SHR-2906 Injection

08:57

Dec15

Hengrui Medicine Receives Clinical Trial Approvals for Four Products

00:22

Dec13

2025 National Medical Insurance Drug Directory Update, Hengrui and Eli Lilly are Major Winners

03:47

Dec12

Hengrui Medicine's Subsidiary Receives Clinical Trial Approval Notice for RSS0343 Tablets from NMPA

11:57

HRS9531 Injection Approved for Clinical Trials by Huahai Medicine's Subsidiary

11:53

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(CST)

FY2025 Q3 Earning Release (CNY) Revenue 7.427 B, Net Income 1.301 B, EPS 0.195

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (CNY) Revenue 8.556 B, Net Income 2.576 B, EPS 0.3982

May23

Distribution Plan(CST)

Cash dividend 0.2 CNY

View More

Stock List

Top Gainers

Top Decliners

Northbound Connect

Symbol

Price

%Chg

Change

View More